文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

RANKL抑制剂地舒单抗联合双免疫检查点抑制与血清CXCL-13浓度升高相关

The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations.
PubMed 文献 · Eur J Cancer · 2024-03-02

这项前瞻性多中心临床试验在不适合手术的IV期黑色素瘤骨转移患者中,将地舒单抗与双免疫检查点抑制剂(ICI)联合使用(BONEMET),并与回顾性对照队列比较。联合治疗组血清CXCL-13升高更显著、VEGFc显著下降,12周时外周初始T细胞减少、CD8+效应细胞增加。作者认为地舒单抗可能增强免疫效应。

要点

  • BONEMET组16例与对照组18例治疗4周后17种细胞因子(含IFNγ)均显著升高。
  • 联合地舒单抗组CXCL-13升高更显著、VEGFc显著下降。
  • 12周时联合组外周初始T细胞显著减少、CD8+效应细胞增加。

核心结论

  • 地舒单抗联合双ICI可调节外周血细胞因子表达和T细胞组成。
  • CXCL-13上调强化了地舒单抗确实增强免疫效应的假说。

研究设计与样本

  • 前瞻性多中心临床试验(BONEMET),纳入不适合手术的IV期黑色素瘤骨转移患者,接受地舒单抗联合双ICI治疗。
  • BONEMET组16例,在基线及治疗开始后4、12、24周进行免疫监测,次要终点包括耐受性和疗效。
  • 回顾性对照队列18例为未接受地舒单抗的双ICI治疗黑色素瘤患者,并做相应生物标本分析。

主要发现

  • BONEMET组(n=16)和对照队列(n=18)治疗4周后17种细胞因子(包括IFNγ)血清水平均显著升高。
  • 与对照队列相比,接受ICI联合地舒单抗的患者血清CXCL-13升高更显著、VEGFc显著下降。
  • 4周时T细胞组成无变化;BONEMET组12周时外周初始T细胞显著减少、CD8+效应细胞增加。
  • 治疗相关不良事件发生率相近:BONEMET组93.8% vs 对照队列83.3%。
  • 疾病控制:BONEMET组7/16例 vs 对照队列8/18例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 对照队列为回顾性参考队列。
  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent evidence suggests additional immunomodulatory properties of RANKL inhibition possibly boosting the clinical efficacy of immune checkpoint inhibitors (ICI). METHODS: We conducted a prospective, multicentre clinical trial in unresectable stage IV melanoma patients with bone metastases who received denosumab in parallel with dual ICI (BONEMET) and performed comprehensive immune monitoring at baseline and 4, 12, and 24 weeks after initiation of therapy. Secondary endpoints included tolerability and efficacy. For comparison, biospecimens from melanoma patients treated with dual ICI without denosumab were analyzed accordingly and served as retrospective reference cohort. RESULTS: In both the BONEMET (n = 16) and the reference cohort (n = 18) serum levels of 17 cytokines, including IFNγ were significantly increased after 4 weeks of treatment. Patients who received ICI and denosumab showed a significantly higher increase in serum CXCL-13 and a significant decrease in VEGFc compared with the reference cohort. While no changes in T cell composition were observed at 4 weeks, patients in the BONEMET cohort showed a significant decrease in the peripheral naïve T-cell population and an increase in CD8+ effector cells after 12 weeks. Treatment-related adverse events occurred with comparable frequency (93.8% in the BONEMET cohort versus 83.3% in the reference cohort). 7/16 patients in the BONEMET cohort and 8/18 patients in the reference cohort achieved disease control. CONCLUSION: Denosumab in combination with dual ICI modulates cytokine expression and T-cell composition in peripheral blood. The upregulation of CXCL-13, a key factor for initiating tertiary lymphoid structures, strengthens the hypothesis that denosumab indeed boost immunological effects.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schaper-Gerhardt K, Gutzmer R, Angela Y, et al. The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations. Eur J Cancer. 2024. PMID: 38479119. doi:10.1016/j.ejca.2024.113984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。